Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment - Archive ouverte HAL Access content directly
Journal Articles Science Advances Year : 2019

Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment

(1, 2) , (2) , (2) , (3) , (4) , (1) , (5) , (6, 7, 8) , (6, 7, 8) , (9) , (10) , (11, 12, 13) , (1) , (4) , (14) , (7, 8) , (15) , (16, 8) , (13, 11, 12) , (1) , (17) , (3, 14) , (2)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Abstract

Type I interferons are highly potent cytokines essential for self-protection against tumors and infections. Deregulations of type I interferon signaling are associated with multiple diseases that require novel therapeutic options. Here, we identified the small molecule, IT1t, a previously described CXCR4 ligand, as a highly potent inhibitor of Toll-like receptor 7 (TLR7)-mediated inflammation. IT1t inhibits chemical (R848) and natural (HIV) TLR7-mediated inflammation in purified human plasmacytoid dendritic cells from blood and human tonsils. In a TLR7-dependent lupus-like model, in vivo treatment of mice with IT1t drives drastic reduction of both systemic inflammation and anti-double-stranded DNA autoantibodies and prevents glomerulonephritis. Furthermore, IT1t controls inflammation, including interferon α secretion, in resting and stimulated cells from patients with systemic lupus erythematosus. Our findings highlight a groundbreaking immunoregulatory property of CXCR4 signaling that opens new therapeutic perspectives in inflammatory settings and autoimmune diseases.
Fichier principal
Vignette du fichier
eaav9019.full.pdf (5.24 Mo) Télécharger le fichier
Loading...

Dates and versions

pasteur-02282952 , version 1 (10-09-2019)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Nikaïa Smith, Mathieu Rodéro, Nassima Bekaddour, Vincent Bondet, Yasser Ruiz-Blanco, et al.. Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment. Science Advances , 2019, 5 (7), pp.eaav9019. ⟨10.1126/sciadv.aav9019⟩. ⟨pasteur-02282952⟩
385 View
144 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More